The Board of Directors of AegirBio AB (“AegirBio” or “the Company”) has, on the authority of the Annual General Meeting on June 28, 2021, resolved on a directed new issue of 490,000 shares to Modelio Equity AB (publ), Modelity Capital AB, CapMate Aktiebolag and Oliver Molse. The subscription price amounts to SEK 260 per share, and the proceeds from the issue total MSEK 127.4. In addition, the Company has obtained debt financing of MSEK 75 from Modelio Equity AB.

The capital contribution of MSEK 202.4 will primarily be used to finance the acquisition of Dynamic Code AB (publ), which was disclosed by the Company at 08:30 today, and to enable future acquisitions.

 

New issue

The professional investors allotted shares in the new issue are: Modelio Equity AB (publ), Modelity Capital AB, CapMate Aktiebolag, and Oliver Molse. The directed new issue will provide the Company MSEK 127.4 in proceeds before transaction costs. The subscription price amounts to SEK 260 per share and includes the usual issue discount of approximately 11.1 percent on the latest closing price of the Company’s share on Nasdaq First North Growth Market, or approximately 10.6 percent on the volume-weighted average share price (VWAP) during the 15 preceding days of trading, which in the Company’s assessment is on market conditions for this type of transaction.

The reason for carrying out the directed issue, and the reasons for the deviation from the shareholders’ preferential rights, were that it enables the Company to acquire working capital in a sufficiently time- and cost-efficient manner to make use of future opportunities, gain strong, long-term owners, and finance the Company's acquisitionof Dynamic Code AB (publ), which was disclosed by the Company at 08:30 today. 

Following the directed issue, the total number of shares and votes in the Company will increase by 490,000, from the current 16,834,062 to 17,324,062. The share capital will increase by SEK 39,200.00, from the current SEK 1,346,724.96 to SEK 1,385,924.96. This corresponds to a dilution of approximately 2.83 percent based on the total number of shares in the Company after the transaction. 

Debt financing

AegirBio has secured debt financing of MSEK 75. The duration of the loan is until it is repaid, but at the latest until December 31, 2021. The terms of the loan are deeemed by the Company to be on market conditions. The lender is Modelio Equity AB (publ).

Rationale

The capital contribution, totaling MSEK 202.4, will primarily be used to finance the acquisition of Dynamic Code AB (publ), which was disclosed by the Company at 08:30 on September 17, 2021, and to enable additional acquisitions.

Lending of shares

In order to facilitate the delivery of shares in the directed issue, Martin Linde and Anders Ingvarsson will lend 490,000 shares to the investors in the directed issue. The borrowed shares will be returned when the directed new issue is registered with the Swedish Companies Registration Office.

Advisors

Eminova Partners AB is the financial advisor and Moll Wendén Advokatbyrå AB is the legal advisor to AegirBio in connection with the directed share issue and the debt financing. 

This information is information that AegirBio AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08:40 on September 17, 2021.

Certified adviser for the Company is Eminova Fondkommission AB  | +468-684 211 10 | adviser@eminova.se.

For more information, please contact:

Anders Ingvarsson, Chairman of the Board, Aegirbio AB
E-mail: aingvarsson@aegirbio.com
Telephone: +46 706 791 878

Martin Linde, CEO Aegirbio AB
E-mail: mlinde@aegirbio.com
Telephone: +46 706 730 968